Approximately 40% of non-muscle invasive bladder cancer patients who are treated with Bacillus Calmette-Guerin will experience treatment failure and recurrence.
Many patients either refuse or are medically unfit for radical cystectomy.
We aim to determine the efficacy and long-term durability of the novel triplet intravesical regimen of docetaxel, gemcitabine, and cisplatin as treatment for these patients.
